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Abstract
Despite multiple studies reporting marked benefit of botulinum toxin (BTX) for
treatment of cricopharyngeal dysphagia, little is known about its safety for this indication.
We examined the safety of cricopharyngeal BTX for dysphagia in oculopharyngeal
muscular dystrophy (OPMD). We reviewed records of patients with OPMD who
received cricopharyngeal BTX. Twenty-four patients underwent 66 procedures. Overall
adverse event frequency was 44%. The most common adverse events were dysphonia
(24%) and worsened dysphagia (14%). Logistic regression demonstrated that dose was a
significant predictor of worsened dysphagia (P=0.036) and of the composite event of
dysphonia or worsened dysphagia (P=0.009). There was a non-significant trend for dose
as a predictor of dysphonia (P=0.073). 59% of procedures were associated with
symptomatic improvement. While BTX appears to be beneficial for treatment of
dysphagia in OPMD, caution is warranted when injecting the cricopharyngeus muscle
due to dose-related risk of dysphonia or worsened dysphagia.
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Chapter 1
Introduction

Oculopharyngeal muscular dystrophy (OPMD) is a late-onset, autosomal
dominant muscle disease characterized by dysphagia, ptosis, and limb weakness.1,2
Radiologic and manometric studies of OPMD have shown that the upper esophageal
sphincter (UES) obstructs bolus transit.3,4 The cricopharyngeus (CP) muscle, the major
component of the UES, is normally tonically active at rest and relaxes during swallow.5
In OPMD, weak pharyngeal contractions are ineffective in transporting boluses across the
UES.6,7 Surgical myotomy of the UES lowers sphincter pressure and improves
swallowing in OPMD6-11 but poses serious risks, including post-surgical fistula,
pneumonia, and death.12
An alternative to surgery is chemical myotomy using botulinum toxin (BTX). To
date, 33 observational studies have reported 300 adults, including 6 with myopathy,13-17
who received BTX for cricopharyngeal dysphagia of disparate causes. The aggregate
improvement rate was 73% (Table 1, Appendix). All 6 patients with myopathy
improved, including 2 with OPMD.13,14
Given the proximity of the CP muscle to posterior arytenoid and inferior
pharyngeal muscles and the risk of local diffusion of BTX, transient dysphonia and
worsened dysphagia are expected adverse events (AEs).18 Remarkably, only 11% of
individuals in prior studies experienced any AE, and only 3% experienced dysphonia or
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worsened dysphagia (Table 1, Appendix). No prior study of cricopharyngeal BTX
examined the relationship between dose and AEs.
We encounter many patients with OPMD at our center due to high disease
prevalence in New Mexico.19 We sought to better characterize risks associated with
cricopharyngeal BTX in OPMD.

3

Chapter 2
Material and Methods

We reviewed health records of all patients with a confirmed diagnosis of OPMD20
who had at least 1 cricopharyngeal BTX injection at our center between January 1, 2000
and December 31, 2011. This study was approved by the local institutional review board.
Requirement for informed consent was waived since the study was a retrospective chart
review. AEs and symptomatic improvement were ascertained by reviewing notes in the
6-month period after each procedure. Two of the 66 procedures (3%) were not followed
by a clinic visit. In these cases, missing data were imputed as follows: no AE and no
improvement.
We used generalized linear mixed models (GLIMMIX in SAS 9.3) to identify
predictors of worsened dysphagia, dysphonia, and a composite event defined as
dysphonia or worsened dysphagia. These models account for correlations due to repeated
procedures on the same individual. If the likelihood ratio test of the random effect
(individual patient) in the generalized linear mixed model was not significant, then the
model was reduced to simple logistic regression, where each procedure was considered to
be independent. All initial models included the following variables: age, gender, dose,
procedure type (percutaneous or endoscopic), injection site (bilateral or unilateral), and
time since last injection. We included the last term to account for residual effects from
any previous injection. We used backward elimination to remove non-significant
predictors. P-values < 0.05 were considered significant.
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Chapter 3
Results

Sixty-six BTX injections were administered to 24 patients with OPMD (mean age
63 ± 8 years, mean age of dysphagia onset 52 ± 5 years, 14 men, 100% Hispanic). Of 19
patients who had videofluoroscopic swallowing studies before the first injection, 14 had
CP prominence or reduced CP opening.
The median number of procedures per patient was 3 (range 1-13). For individuals
with more than 1 procedure, the median time between treatments was 6 months (range 239). Median onabotulinumtoxinA (Botox®, Allergan, Irvine, CA) dose was 20 units
(range 10-30). All but 3 procedures were performed by the same otolaryngologist. Toxin
was injected either percutaneously with electromyographic guidance (88%) or
endoscopically with direct visualization (12%). Sixty-eight percent of procedures
involved bilateral cricopharyngeal injections; the rest were unilateral.
AEs occurred after 44% of procedures, and 19 of 24 individuals had at least 1 AE.
The most common AEs were transient dysphonia and worsened dysphagia, which
occurred after 24% and 14% of procedures, respectively. Other AEs included dizziness
or syncope (8%), reflux (5%), injection site pain (5%), rash (2%), and laryngospasm
(2%). In 10 cases, the duration of dysphonia after treatment was recorded and ranged
from 1 week to 4 months. There were 2 serious AEs requiring brief hospital visits (one
patient with 3 episodes of syncope immediately after the procedure and a second patient
with laryngospasm and respiratory distress within 1 day of the procedure).
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Likelihood ratio tests of the random effect (individual patient) in the generalized
linear mixed models were not significant for any of the 3 dependent variables (worsened
dysphagia: P=0.15, dysphonia: P=0.34, composite event of dysphonia or worsened
dysphagia: P=0.23). Logistic regression demonstrated that dose is a significant predictor
of worsened dysphagia (P=0.036) and of the composite event (P=0.009). There was a
non-significant trend for dose as a predictor of dysphonia alone (P=0.073). See Figure 1
below. Age, gender, procedure type, injection site, and time since last injection were not
significant predictors in any model. For a 10-unit increase in dose, the odds ratio (OR)
for worsened dysphagia was 3.92 (95 % C.I. 1.09,14.05), the OR for dysphonia was 2.40
(95% C.I. 0.92, 6.26), and the OR for the composite event was 3.49 (95% C.I. 1.36,
8.95).
Physicians documented symptom improvement following 59% of procedures.

6

Figure 1. Logistic dose-response
models were fit to the data. Estimated
probabilities of dysphonia (top panel),
worsened dysphagia (middle panel),
and the composite event of dysphonia
or worsened dysphagia (lower panel)
increase as a function of dose. The yaxes represent estimated probabilities.
Solid black curves represent the results
of the models for each adverse event.
Gray regions represent 95% confidence
intervals. Open circles indicate actual
doses for each procedure and are
displayed with jitter to make identical
values visible.
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Chapter 4
Discussion

This study examined the safety of BTX for treatment of cricopharyngeal
dysphagia in a large number of cases with a single myopathy. Our observed 44% AE
rate contrasts with the 11% AE rate reported in prior studies (Table 1, Appendix).
Doses in prior studies varied from 5 to 120 Botox®-equivalent units. While some
have predicted that injection of 100 units in the CP muscle would likely cause dysphonia
and worsened dysphagia through local toxin diffusion,18 none of 54 individuals who
received ≥100 units in prior studies were reported to experience an AE (Table 1,
Appendix). Furthermore, only 3% of 300 individuals in prior studies were reported to
experience dysphonia or worsened dysphagia, and no study demonstrated a link between
dose and AEs (Table 1, Appendix). In contrast, our study shows that dysphonia and
worsened dysphagia are dose-related AEs, and provides estimates for the magnitude of
AE risk at different doses.
AE risk may depend on the etiology of dysphagia. Given the peripheral
mechanism of action of BTX, individuals with muscle or lower motor neuron disorders
may be more prone to AEs. Yet, none of 6 individuals with myopathy who received
cricopharyngeal BTX in prior studies experienced dysphonia or worsened dysphagia.13-17
Moreover, a recent study that evaluated the benefit of cricopharyngeal BTX in 20 patients
with amyotrophic lateral sclerosis reported no complications in the sub-group with lower
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motor neuron bulbar weakness.21 Ours quantifies the risks of cricopharyngeal BTX
specifically in muscle disease.
Although our study could not assess efficacy since there was no untreated
comparison group and validated dysphagia outcome measures were not used, subjective
improvement followed 59% of procedures. Given potential for benefit, a controlled trial
is warranted. Until then, we emphasize the need for caution when administering BTX to
the CP muscle.
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Appendix
Table 1. Summary of 33 prior studies of botulinum toxin injection for treatment of cricopharyngeal dysphagia in adults. a
Study
Dunne et al., Lancet 1993;
342(8870):559
Schneider et al., Ann Otol
Rhinol Laryngol
1994;103(1):31-35
Crary et al., Arch
Otolaryngol Head Neck
Surg 1996;122(7):760-763
Atkinson et al., J
Otolaryngology
1997;26(4):273-276
Blitzer et al., Otolaryngol
Head Neck Surg
1997;116(3):328-330
Brant et al., Dis Esophagus
1999;12(1):68-73
Alberty et al.,
Laynrgoscope
2000;110(7):1151-1156
Restivo et al.,
Gastroenterology
2000;119(5):1416
Ahsan et al., Otolaryngol
Head Neck Surg
2000;122(5):691-695
Shaw et al., Dysphagia
2001;16(3):161-167
Haapaniemi et al.,
Dysphagia
2001;16(3):171-175
Moerman et al., Eur Arch
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2002;259(1):1-3.
Restivo et al., N Engl J
Med 2002;346(15):11741175
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1
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0
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1

neck cellulitis
after
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surgery

Marchese-Ragona et al.,
Ann Otol Rhinol Laryngol
2003;112(3):258-263

5

0

0

5

10-16

P

5

2

aerophagia (1),
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1
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aspiration
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Table 1. Summary of 33 prior studies of botulinum toxin injection for treatment of cricopharyngeal dysphagia in adults. a
Liu et al., Can J
Gastroenterol
2
0
2
0
100
E
2
0
2004;18(6):397-9
Chiu et al., Dysphagia
1
1
0
0
120
E
1
0
2004;19(1):52-7
Murry et al., Am J
1
Otolaryngol
7
3
3
100
P
11
0
3
2005;26(3):157-62
Kim et al., Arch Phys Med
Rehabil.
8
8
0
0
100
E
5
0
2006;87(10):1346-51
Masiero et al., J Rehabil
2
2
0
0
25-30
P
2
0
Med 2006;38(3):201-3
Restivo et al., Diabetes
1
Care 2006;29(12):26500
12
0
20
P
12
0
2
2653
Restivo et al., J Neurol
2
2
0
0
10
P
2
0
2006;253(3):388-389
transient
Suzukia et al., Brain Dev
1
0
1
0
5
P
1
1
worsened
2007;29(10):662-665
dysphagia
Krause et al., Dysphagia
1
1
0
0
60
E
1
0
2008;23(4):406-410
Oh et al., Am J Phys Med
Rehabil 2008;87(11):8832
0
2
0
NRj
NR
0
0
889
Terre et al., Scand J
1
Gastroenterol
10
0
0
100
E
8
0
0
2008;43(11):1296-1303
Alfonsi et al., J Neurol
3
Neurosurg Psychiatry.
34
0
0
15
P
17
0
4
2010;81(1):54-60
Natt et al., Auris Nasus
1
pain at injection
Larynx 2010;37(4):5000
0
15
100
P
13
1
5
site
503
Restivo et al., Eur J Neurol 1
14
0
0
20
P
14
0
2011;18(3):486-490
4
transient
worsened
dysphagia
(number NR),
chest pain (2),
Kelly et al., Ann Otol
4
15congestion (1),
Rhinol Laryngol
NR
NR
NR
P or E
32
16
9
100
belching
2013;122(2):100-108
(number NR),
increased mucus
(number NR),
reflux (number
NR)
transient
Woisard-Bassols et al.,
1
worsened
Eur Arch Otorhinolaryngol
4
7
0
25-60
P
5
3
1
dysphagia (2),
2013;270(3):805-815
reflux (2)
Restivo et al., Neurology
2
13
7
0
10
P
11
0
2013;80(7):616-620
0
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a

We searched PubMed (1947-July 2013) using the search strategy: “Botulinum
Toxins”[Mesh] AND “Deglutition Disorders”[Mesh]. The search yielded 386 titles.
Inclusion criteria: any observational (including case reports or case series) or
experimental study of botulinum toxin for cricopharyngeal dysphagia. Exclusion criteria:
studies in infants or children. References of relevant articles were reviewed. 33 articles
met inclusion/exclusion criteria and underwent full-text review.
b
CNS: central nervous system etiology (e.g. stroke, bulbar palsy, Parkinson’s disease)
c
PNS: peripheral nervous system etiology (e.g. cranial nerve palsies, spinal muscular
atrophy, myopathy,)
d
Non-neurologic etiology (e.g. Zenker’s diverticulum, post-pharyngectomy, postlaryngectomy; idiopathic cricopharyngeal dysfunction)
e
Dose: Botox®-equivalent units (Dysport®:Botox® conversion ratio 3:1)
f
Method: P – percutaneous (guidance by electromyography, computed tomography, or
videofluoroscopy); E – endoscopic; O – open surgical technique
g
Improved: number of individual reported to have clinically improved (note: outcome
measures varied across studies)
h
AE: number of individuals reported to have experienced at least one adverse event
i
AE Type: type of adverse event (number of adverse events in parentheses)
j
NR: not reported
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